A 52-Year-Old Woman with Intermediate-Risk Primary Myelofibrosis

Srdan Verstovsek, MD, PhD, provides insight on treatment of primary myelofibrosis, including ruxolitinib, and comments on some of the challenges, unmet needs, and future directions in the field.